Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Clin Investig Arterioscler ; 32(6): 231-241, 2020.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-32605806

RESUMO

OBJECTIVE: To present the first registry used to analyse the clinical profile of patients treated with evolocumab in Spain, including the effectiveness on the lipid profile and safety in the «real world¼ setting. METHODS: Multicentre, retrospective, and observational study of patients starting treatment with evolocumab from February 2016 to May 2017 in clinical practice in Spanish cardiology units. RESULTS: A total of 186 patients (mean age 60.3 ± 9.8 years were included, 35.5% with familial hypercholesterolaemia, and 94.1% with a previous cardiovascular event) from 31 cardiology units. Baseline lipid profile: Total cholesterol 219.4 ± 52.2 mg/dL, LDL-cholesterol 144.0 ± 49.0mg/dL, HDL-cholesterol 47.7 ± 13.0mg/dL, and triglycerides 151.0 ± 76.2mg/dL. At the time of initiating evolocumab, 53.8% of patients were taking statins (50% had partial or total intolerance to statins), and 51.1% ezetimibe. In all cases, the dose of evolocumab used was 140 mg, mainly every 2 weeks (97.3%). Evolocumab compliance was high (92.3%). Treatment with evolocumab was interrupted in 6 patients (3.2%), with only 1 (0.5%) due to a probable side effect. Evolocumab significantly reduced total cholesterol (30.9% at week 2, and 39.3% at week 12; P<.001), LDL cholesterol (44.4% and 57.6%, respectively; P<.001), and triglycerides (14.8% and 5.2%, respectively; P<001), with no significant changes in HDL-cholesterol (6.7% and 2.0%; P=.14). CONCLUSIONS: In clinical practice, evolocumab is associated with reductions in LDL cholesterol, with nearly 60% after 12 weeks of treatment, and with low rates of interruptions due to side effects and high medication compliance. These results are consistent with those reported in randomised clinical trials.


Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Anticolesterolemiantes/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Sistema de Registros , Idoso , Anticorpos Monoclonais Humanizados/efeitos adversos , Anticolesterolemiantes/efeitos adversos , Serviço Hospitalar de Cardiologia/estatística & dados numéricos , Doenças Cardiovasculares/sangue , Colesterol/sangue , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Ezetimiba/efeitos adversos , Ezetimiba/uso terapêutico , Feminino , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hipercolesterolemia/sangue , Hipercolesterolemia/prevenção & controle , Hiperlipoproteinemia Tipo II/sangue , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Hiperlipoproteinemia Tipo II/prevenção & controle , Masculino , Pessoa de Meia-Idade , Prevenção Primária , Estudos Retrospectivos , Prevenção Secundária , Espanha , Fatores de Tempo , Triglicerídeos/sangue
2.
Pediatr. día ; 5(1): 29-30, mar.-abr. 1989. ilus
Artigo em Espanhol | LILACS | ID: lil-79341

RESUMO

La oftalmoscopía es una técnica de exploración basada en la iluminación del fondo del ojo del paciente y la observación de la zona iluminada a través de un sistema óptico. Hoy en día existen diferentes tipos de oftalmoscopios, ya sea de visión directa o indirecta, con o sin la ayuda de lentes de contacto, etc..., pero el más usado por casi todos los médicos es el oftalmoscopio directo, dejando el resto de complicado manejo y onerosa adquisición para el uso de los oftalmólogos especializados. Se pretende dar una mínima pauta de manejo práctico del oftalmoscopio, tanto para el estudio del fondo de ojo, como para otros fines, tales como la búsqueda de rojo pupilar y la búsqueda grosera de desviaciones (Hisberg) que ayudan a la detección de otras patologías oculares


Assuntos
Oftalmoscopia/instrumentação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA